RATIONALE

Pituitary neuroendocrine tumour (Pit-NET) represents a complex disease. The clinical manifestations of Pit-NETs are multiple and heterogeneous, according to the ability of secreting different hormones or pro-hormones and of invading the neighbouring anatomical structures, such as the same pituitary gland, the optical chiasm, the cavernous sinus, the bone, the third ventricle and the ventricular system.

In the most recent years, a better definition of these neoplasia was researched in order to identify biomarkers able to predict the natural history of Pit-NET and their responsiveness to the different treatments.

Until now, the classifications of the neoplasms arising from adeno-hypophysial cells have been misleading because of their poor reproducibility and their weak ability in predicting the aggressiveness, the prognosis, and the outcome of these neoplasia. The 2004 WHO classification distinguished pituitary adenoma in typical and atypical ones according to the detection of mitoses and according to the expression of Ki-67 or p53. The 2004 WHO classification however failed in identifying pituitary tumours refractory to medical, surgical or radiation therapies or able to regrowth or to metastasize. Similarly, the new 2017 WHO classification lacks in defining the prognosis of pituitary neoplasia. Invasive, recurrent and proliferative pituitary neoplasia cause significant morbidity, in particular in cases of persistence hormonal hyper-secretion. Both long term hormonal hyper-secretion and hypopituitarism, in absence of an adequate hormonal replacement therapy, are associated to increased morbidity and mortality for their systemic complications.

Therefore, recently, pituitary adenomas were recognised as neuroendocrine tumors (NETs). This new terminology of pituitary neuroendocrine tumor (PitNET) reflects better the potential for aggressiveness and malignant behaviour and of these neoplasia.
On this basis, in the recent years, a wide number of research investigated the genetic, molecular and biological features of PitNET, in order to predict the clinical behaviour of these neoplasia. The current event, has the aim of updating participants on the latest biological, genetic and clinical acquisitions on PitNET and on their impact in the management of PitNet affected patients.

The meeting is part of the teaching activities of the Master Degree in Diagnosis and Treatment of pituitary disease (2019) - Faculty of Medicine, Universita' Cattolica del Sacro Cuore, Rome.

DIRECTOR Prof. **ALFREDO PONTECORVI**
Professor of Endocrinology
Fondazione Policlinico Universitario A. Gemelli
Università Cattolica del Sacro Cuore, Rome

RESPONSABILE SCIENTIFICO
Prof.ssa Laura De Marinis
Coordinatore Scientifico del Master Universitario di II Livello in diagnosi e terapia delle patologie ipotalamo ipofisarie - Policlinico Universitario A. Gemelli, Roma

SEGRETERIA SCIENTIFICA
Coordinatori: **Dott. Antonio Bianchi, Dott.ssa Antonella Giampietro**
Massimiliano Andrioli **Sabrina Chiloiro** **Domenico Milardi** **Serena Piacentini**
Chiara Bima **Giuseppe Grande** **Marilda Mormando** **Linda Tartaglione**
U.O.S. di Patologia Ipotalamo – Ipofisaria, Policlinico Universitario A. Gemelli, Roma

SEDE
Hotel Donna Camilla Savelli
Via Garibaldi, 27 - Roma - Tel. 06 588861

ECM 680 - 275782
L'evento rientra nel piano formativo ECM 2019 della DOTCOM s.r.l. ed è rivolto alle figure professionali di **Infermiere** e di **Medico - Chirurgo** per le seguenti discipline: Anatomia Patologica, Chirurgia Generale, Endocrinologia, Gastroenterologia, Genetica Medica, Malattie Metaboliche e Diabetologia, Medicina Interna, Medicina Nucleare, Neurochirurgia, Neuroradiologia, Oftalmologia, Otorinolaringoiatria, Patologia Clinica (Laboratorio di Analisi Chimico- Cliniche e Microbiologia), Radiodiagnostica, Radioterapia.

Assegnati n. 12 Crediti Formativi ECM

PRE-ISCRIZIONE
L'iscrizione è gratuita e potrà essere effettuata inviando un email al seguente indirizzo: info@dotcomeventi.com
L'accesso in aula è riservato ai primi 100 partecipanti. Si ricorda che l'attestazione dei crediti ottenuti è subordinata alla partecipazione del 90% della durata dei lavori, alla compilazione della scheda di valutazione dell'evento e al superamento della prova di apprendimento (questionario, almeno 75% risposte esatte).

OBIETTIVO FORMATIVO
Documentazione Clinica. Percorsi Clinico-Assistenziali Diagnostici e Riabilitativi, Profili di Assistenza - Profili di Cura

PROVIDER E SEGRETERIA ORGANIZZATIVA
dotcom srl
Via Flaminia, 54 | 00196 Roma
Tel. 06 4061370 | Fax 06 3242600 | E-Mail: info@dotcomeventi.com | **www.dotcomeventi.com**

Lingue ufficiali: Italiano/Inglese

Con la sponsorizzazione non condizionante di

NOVARTIS · IPSEN Innovation for patient care · Pfizer · HRA Pharma Rare Diseases

Artwork: Simona Reniè - *Stampa:* Messere, Roma

6th ANNUAL MEETING ON PITUITARY TUMORS

Update on the biological and molecular mechanisms in Pit-NET and their relationship with the personalized therapy

ROME
28th 29th
November 2019
Hotel Donna Camilla Savelli

Con il Patrocinio di

AME · sie Società Italiana Endocrinologia

UNIVERSITÀ CATTOLICA del Sacro Cuore

Gemelli
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Università Cattolica del Sacro Cuore

Responsabile Scientifico
Laura De Marinis

www.ipofisicrescitadintorni.it

1st DAY | *Thursday, 28th* November 2019

12.30 *Welcome Light Lunch*
Registration

13.30 Introduction: **L. De Marinis**

Welcome Speech: **R. Bellantone, G. Carpani, A. Lenzi, A. Olivi, G. Paludetti, A. Pontecorvi, P. Pozzilli, G. Scambia, A. Scoppola**

14.00 Treatment challenges and the doctor-patient relationship - **L. Festa (ANIPI)**

PRESIDENTIAL LECTURE
Chairmen: **A. Lenzi, A. Pontecorvi**

14.10 European Community policies in endocrine and metabolic diseases - **A. Giustina**

14.50 The Pituitary Tumor Centers of Excellence - **F. Casanueva**

I SESSION - New genetic knowledge and acquisitions on PitNETs
Chairmen: **E. De Menis, M. L. Jaffrain-Rea, M. Zollino**

15.30 ACTH secreting pituitary tumors: from adenoma to carcinoma – **S. Cannavò**

15.50 Somatic and germline changes in pituitary neuroendocrine tumours, PitNETs - **M. Korbonits**

16.10 *Coffee Break*

16.30 The genetic basis of Pit-NETs among the endocrine syndromes - **E. D. Capoluongo**

16.50 New approaches in the medical treatment of GH secreting PitNET: rule of the regulators of the cell metabolism - **M. C. Zatelli**

17.10 Discussion

II SESSION - DEBATE
Chairmen: **S. Grottoli, A. Lania**

17.30 The impact of the pathological assessment of PitNET on the management of affected patients: Pros and cons - **A. Bianchi, D. Ferone**

18.30 Conclusions

2nd DAY | *Friday, 29th* November 2019

08.00 Registration

LECTURE
Chairmen: **V. Toscano, P. Zuppi**

08.30 New knowledges on hormonal replacement therapy of growth hormone deficit in PitNET - **A. Giampietro**

III SESSION - New pathological knowledges and acquisitions on PitNETs
Chairmen: **G. Rindi, C. Scaroni**

09.00 Sex-related differences and clinical, pathological and molecular factors of aggressiveness of lactotroph tumours - **J. Trouillas**

09.30 Criteria and controversies of the microscopic classification of pituitary neuroendocrine tumours: are transcription factors the answer? **F. Roncaroli**

10.00 How the new biological and molecular knowledges may impact on the medical management of not secreting PitNET? - **G. Mantovani**

10.30 Discussion

10.45 *Coffee Break*

LECTURE
Chairmen: **A. Fabbri**

11.00 How the meta-analysis may impact on the medical management of GH secreting PitNET? **A. Isidori**

11.20 How to Position Pegvisomant and Pasireotide LAR Treatment in Acromegaly? **EC Coopmans**

IV SESSION - New genetic and molecular knowledges in the multidisciplinary approach of PitNET in Pituitary Tumor Centers of Excellence
Chairmen: **G. Arnaldi, P. Gargiulo, M.V. Davì**

11.40 Role of the expert in osteoporosis - **S. Frara, A. Spada**

12.00 Role of the expert in neuroradiology - **T. Tartaglione**

12.20 Role of the expert in radiotherapy - **S. Chiesa, G. Minniti**

12.40 Role of the expert in translational medicine - **F. Gatto**

13.00 Role of the expert in pituitary pathology - **M. Gessi**

13.20 Discussion

13.40 *Light Lunch*

V SESSION - TERAPIA CHIRURGIA: How the new biological and molecular knowledges may impact on the neuro-surgical management of PitNET?
Chairmen: **C. Anile, A. Olivi,**

14.40 The experts in neurosurgery - **F. Doglietto, L. Lauretti**

15.20 The expert in otorinoloaringoiatry - **M. Rigante**

15.40 Discussion

VI SESSION: How the new biological and molecular knowledges may impact on the medical therapies of PitNET?
Chairmen: **R. Baldelli, M. Poggi**

15.50 ACTH secreting PitNET - **R. Pivonello**

16.10 GH secreting PitNET - **G. Mazziotti**

16.30 Not secreting PitNET - **P. Maffei**

16.50 Prolactin secreting PitNET - **S. Chiloiro**

17.10 Discussion

17.30 CME evaluation

FACULTY

Carmelo Anile, *Roma*
Giorgio Arnaldi, *Ancona*
Roberto Baldelli, *Roma*
Rocco Bellantone, *Roma*
Antonio Bianchi, *Roma*
Salvatore Cannavò, *Messina*
Ettore Domenico Capoluongo, *Roma*
Guido Carpani, *Roma*
Felipe Casanueva, *Santiago De Compostela*
Silvia Chiesa, *Roma*
Sabrina Chiloiro, *Roma*
Eva C. Coopmans, *Rotterdam*
Maria Vittoria Davi', *Verona*
Laura De Marinis, *Roma*
Ernesto De Menis, *Treviso*
Francesco Doglietto, *Brescia*
Andrea Fabbri, *Roma*
Diego Ferone, *Genova*
Lucia Festa, *Roma*
Stefano Frara, *Milano*
Patrizia Gargiulo, *Roma*
Federico Gatto, *Genova*
Marco Gessi, *Roma*
Antonella Giampietro, *Roma*
Andrea Giustina, *Milano*
Silvia Grottoli, *Torino*
Andrea Marcello Isidori, *Roma*
Marie Lise Jaffrain – Rea, *L'Aquila*
Marta Korbonits, *London*
Andrea Gerardo Antonio Lania, *Milano*
Liverana Lauretti, *Roma*
Andrea Lenzi, *Roma*
Pietro Maffei, *Padova*
Giovanna Mantovani, *Milano*
Gherardo Mazziotti, *Rozzano (MI)*
Giuseppe Minniti, *Roma*
Alessandro Olivi, *Roma*
Gaetano Paludetti, *Roma*
Rosario Pivonello, *Napoli*
Maurizio Poggi, *Roma*
Alfredo Pontecorvi, *Roma*
Mario Rigante, *Roma*
Guido Rindi, *Roma*
Federico Roncaroli, *Manchester*
Carla Scaroni, *Padova*
Alessandro Scoppola, *Roma*
Antonio Spada, *Roma*
Tommaso Tartaglione, *Roma*
Vincenzo Toscano, *Roma*
Jacqueline Trouillas, *Lione*
Maria Chiara Zatelli, *Ferrara*
Marcella Zollino, *Roma*
Paolo Zuppi, *Roma*